Dealing with state regulation of the pharma supply chain

Why they are a game changer, and ways to a adapt to a new era of state privacy regulations.

Dave DeJean provides his expert insight on lessons he’s learned from his plethora of time in the industry, along with an outlook on where the pharma supply chain stands in adhering to the Drug Supply Chain Security Act (DSCSA).

If Congress doesn't act soon, it could result in more health inequities.

These advancements continue to act as a key driver in helping to boost the security, efficiency, and innovation of global industries, include pharma.

Study explores how the Inflation Reduction Act’s Drug Price Negotiation Program and its maximum fair prices impact incentives for investments in post-approval activity.

The partnership revolves around augmenting regulatory compliance, along with drug sampling distribution and compliance.